Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:CRMD NASDAQ:CTMX NASDAQ:FBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.43-4.7%$1.85$1.09▼$3.40$166.54M0.6881,069 shs463,910 shsCRMDCorMedix$7.78-7.6%$8.33$6.13▼$14.96$660.57M1.481.28 million shs1.16 million shsCTMXCytomX Therapeutics$3.52-2.8%$3.47$1.72▼$8.21$616.08M2.085.25 million shs5.54 million shsFBRXForte Biosciences$47.49-2.8%$23.67$9.10▼$52.15$678.45M2.85926,438 shs602,220 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-4.67%-5.30%-18.29%-41.87%-10.06%CRMDCorMedix-7.60%-6.49%-10.27%+5.42%-28.36%CTMXCytomX Therapeutics-2.76%-4.86%+19.32%-26.05%+47.90%FBRXForte Biosciences-2.80%+7.64%+166.05%+44.61%+366.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.43-4.7%$1.85$1.09▼$3.40$166.54M0.6881,069 shs463,910 shsCRMDCorMedix$7.78-7.6%$8.33$6.13▼$14.96$660.57M1.481.28 million shs1.16 million shsCTMXCytomX Therapeutics$3.52-2.8%$3.47$1.72▼$8.21$616.08M2.085.25 million shs5.54 million shsFBRXForte Biosciences$47.49-2.8%$23.67$9.10▼$52.15$678.45M2.85926,438 shs602,220 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-4.67%-5.30%-18.29%-41.87%-10.06%CRMDCorMedix-7.60%-6.49%-10.27%+5.42%-28.36%CTMXCytomX Therapeutics-2.76%-4.86%+19.32%-26.05%+47.90%FBRXForte Biosciences-2.80%+7.64%+166.05%+44.61%+366.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.63153.50% UpsideCRMDCorMedix 2.75Moderate Buy$14.8690.97% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10243.75% UpsideFBRXForte Biosciences 2.60Moderate Buy$67.0041.08% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, CRMD, FBRX, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026FBRXForte Biosciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight7/8/2026FBRXForte Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $13.006/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M7.54N/AN/A$0.28 per share5.11CRMDCorMedix$311.71M1.96$1.89 per share4.12$5.14 per share1.51CTMXCytomX Therapeutics$76.20M7.86N/AN/A$0.58 per share6.07FBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)CRMDCorMedix$163.05M$2.133.65778.00N/A45.25%45.57%24.76%8/6/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)Latest ALEC, CRMD, FBRX, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026FBRXForte Biosciences-$1.03N/AN/AN/AN/AN/A8/6/2026Q2 2026ALECAlector-$0.24N/AN/AN/A$1.43 millionN/A8/6/2026Q2 2026CRMDCorMedix$0.26N/AN/AN/A$96.04 millionN/A8/6/2026Q2 2026CTMXCytomX Therapeutics-$0.11N/AN/AN/A$12.39 millionN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25CRMDCorMedix0.332.972.74CTMXCytomX TherapeuticsN/A10.3810.38FBRXForte BiosciencesN/A2.752.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%CRMDCorMedix34.18%CTMXCytomX Therapeutics67.77%FBRXForte Biosciences77.63%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%CRMDCorMedix3.50%CTMXCytomX Therapeutics3.80%FBRXForte Biosciences4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableALEC, CRMD, FBRX, and CTMX HeadlinesRecent News About These CompaniesForte Biosciences, Inc. (NASDAQ:FBRX) Receives Consensus Rating of "Moderate Buy" from Analysts34 minutes ago | marketbeat.comForte Biosciences (NASDAQ:FBRX) Sets New 52-Week High - Should You Buy?2 hours ago | marketbeat.comForte Biosciences (NASDAQ:FBRX) Stock Price Up 7.8% - Here's What HappenedJuly 17, 2026 | marketbeat.comForte Biosciences (NASDAQ:FBRX) Reaches New 12-Month High - Here's WhyJuly 15, 2026 | marketbeat.comCandriam S.C.A. Acquires New Holdings in Forte Biosciences, Inc. $FBRXJuly 15, 2026 | marketbeat.comForte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - SlideshowJuly 13, 2026 | seekingalpha.comForte Biosciences (NASDAQ:FBRX) Trading Down 8.2% - Time to Sell?July 13, 2026 | marketbeat.comForte Biosciences (NASDAQ:FBRX) Rating Increased to Sell at Wall Street ZenJuly 12, 2026 | marketbeat.comForte Biosciences (NASDAQ:FBRX) Sees Large Volume Increase - Here's What HappenedJuly 10, 2026 | marketbeat.comFBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataJuly 10, 2026 | zacks.comForte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable ImprovementJuly 10, 2026 | marketbeat.comForte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication BetJuly 10, 2026 | seekingalpha.comFBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?July 9, 2026 | finance.yahoo.comForte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action TranscriptJuly 9, 2026 | seekingalpha.comForte Biosciences (NASDAQ:FBRX) Reaches New 12-Month High - Still a Buy?July 9, 2026 | marketbeat.comForte Biosciences shares surge after positive phase 1b vitiligo resultsJuly 9, 2026 | proactiveinvestors.comForte Bio surges on early-stage trial data for vitiligo therapyJuly 9, 2026 | seekingalpha.comForte Biosciences shares climb after positive phase 1b vitiligo trial results (FBRX)July 9, 2026 | msn.comFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodJuly 9, 2026 | businesswire.comOne Forte Biosciences Insider Raised Stake By 30% In Previous YearJune 13, 2026 | finance.yahoo.comForte Biosciences: Targeting Celiac DiseaseMay 16, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, CRMD, FBRX, and CTMX Company DescriptionsAlector NASDAQ:ALEC$1.43 -0.07 (-4.67%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$1.43 0.00 (0.00%) As of 07/20/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.CorMedix NASDAQ:CRMD$7.78 -0.64 (-7.60%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$7.93 +0.15 (+1.93%) As of 06:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.CytomX Therapeutics NASDAQ:CTMX$3.52 -0.10 (-2.76%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$3.60 +0.08 (+2.22%) As of 06:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Forte Biosciences NASDAQ:FBRX$47.49 -1.37 (-2.80%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$47.44 -0.05 (-0.11%) As of 04:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
